



# Ethnobotany and the discovery of anti-infectives for the post-antibiotic era

Cassandra L. Quave, Ph.D.


Assistant Professor of Dermatology & Human Health

Curator, Emory University Herbarium

E-mail: [cquave@emory.edu](mailto:cquave@emory.edu)

Lab Website: <http://etnobotanica.us/>

Twitter: @QuaveEthnobot



**Quave Research Group**

Medical Ethnobotany & Anti-Infective Drug Discovery


Casandra L. Quave, Ph.D.

Personal/Professional Financial Relationships with Industry

<b>External Industry Relationships</b>	<b>Company Name</b>	<b>Role</b>
Equity, stock, or options in biomedical industry companies or publishers	PhytoTEK LLC Lifestory Health	CEO/CSO SAB
Board of Directors or officer	PhytoTEK LLC	CEO/CSO
Royalties from Emory or from external entity	None	
Industry funds to Emory for my research	The Coca Cola Company; NatureX; Bionorica SE	PI
Other		

# Overview

- Challenges presented by antibiotic resistance
- Ethnobotany as a key piece to the toolkit for drug discovery
- Examples of discoveries in this arena:
  - Biofilm inhibitors
  - Quorum sensing inhibitors
  - Resistance modifying agents



# *A Dance with Death:* Birth defects, amputation & infection



*You only live twice: Once when you are born and once when you look death in the face.*

*-Ian Fleming, You Only Live Twice, 1964*

*Diagnosis: Congenital absence of the right fibula, shortened tibia and femur, and pseudarthrosis of right ankle*

## Early days of adventure in Florida...from the swamps to the high seas



# Nature, science & medicine



Emergency Room



Land Clearing

Science fair:  
microbiology  
and studies on  
*E. coli*  
infections and  
antibiotic  
resistance




# Rise of the Post-Antibiotic Era


## THE SPREAD OF ANTIBIOTIC RESISTANCE

An increasing proportion of bacteria display resistance to common antibiotics.

- Fluoroquinolones
- Cephalosporins (3rd gen)
- Aminoglycosides
- Carbapenems
- Polymyxins



\*Enterobacteriae, including *Escherichia coli*, *Klebsellia pneumonia*, *Enterobacter* and *Salmonella*



# WHO priority pathogens list for R&D of new antibiotics

## Priority 1: CRITICAL

- *Acinetobacter baumannii*, carbapenem-resistant
- *Pseudomonas aeruginosa*, carbapenem-resistant
- *Enterobacteriaceae*, carbapenem-resistant, ESBL-producing

## Priority 2: HIGH

- *Enterococcus faecium*, vancomycin-resistant
- ***Staphylococcus aureus*, methicillin-resistant, vancomycin-intermediate and resistant**
- *Helicobacter pylori*, clarithromycin-resistant
- *Campylobacter* spp., fluoroquinolone-resistant
- *Salmonellae*, fluoroquinolone-resistant
- *Neisseria gonorrhoeae*, cephalosporin-resistant, fluoroquinolone-resistant

## Priority 3: MEDIUM

- ***Streptococcus pneumoniae*, penicillin-non-susceptible**
- *Haemophilus influenzae*, ampicillin-resistant
- *Shigella* spp., fluoroquinolone-resistant






Shift from natural products to HTS screens of combi-chem libraries & focus on protein targets

# Antibiotic Discovery Void

More than 30-Year Void in Discovery of New Types of Antibiotics



New classes introduced into the market but discovered in the past







FIG. 1. Illustration of the "discovery void." Dates indicated are those of reported initial discovery or patent.

# Latest representatives of novel antibacterial classes

Structure	Name	Class	Year to Market	Year Class Discovered
	Linezolid	Oxazolidinones	2000	1978
	Daptomycin	Acid lipopeptides	2003	1987
	Retapamulin	Pleuromutilins	2007	1952

# Where to find new drugs for MDR infections?



- Environmental samples
  - Soil microbes
  - Marine organisms
  - Endophytes
- “Unculturable” microbes
- Genome mining
- Animal proteins
- **Plants and fungi**



# Plants as a source of medicine



*Willow*  
Aspirin



*Foxglove*  
Digoxin/Digitoxin




*Mayapple*  
Podophyllin/ Etoposide



*Poppy*  
Codeine/ Morphine

# Kew Report: State of the World's Plants 2017

A photograph showing two women in traditional Indian attire, including colorful saris and head coverings, sitting on a large pile of red chili peppers. They are sorting the peppers into two large, shallow, light-colored bowls. The background shows a concrete wall and a field of green plants, likely a chili pepper field. The scene is outdoors and appears to be a processing area for the harvest.

Useful plants

At least 28,187 plant species are currently recorded as being of medicinal use


# Plant natural products in the Nobel Prize spotlight



Dr. Youyou Tu



Ming dynasty version (1574 CE) of the handbook. “A handful of qinghao immersed with 2 liters of water, wring out the juice and drink it all” is printed in the fifth line from the right.



*Artemisia annua* L., Asteraceae

Tu, Y. 2011. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine *Nature Medicine* 17: 1217–1220

# Core Research Approach



Field Work

Herbarium




Microbiology  
& Cell  
Culture

Phyto-  
chemistry



# How to pick a field research location?

- Global Hotspots of Biodiversity
  - As many as 44% of all species of vascular plants confined to 25 hotspots comprising 1.4% of Earth's land surface
    - 25,000 plants native to the Mediterranean basin
    - 13,000 of these are **endemic!**



The 25 hotspots of biodiversity.


Myers, N., et al. 2000. Biodiversity hotspots for conservation priorities. *Nature* 403, 853-858,



# Ethnobotanical Approach to Drug Discovery



**Collection sites:** USA (Oregon, Florida, Georgia); Italy (Basilicata, Sicily, Aegadian Islands, Pantelleria); Albania (NE), Kosovo (Central and SW)



# Why do fieldwork in the Mediterranean?

- High levels of endemism
- High density of biological and cultural diversity
- Different groups may use same ecological resources in very different ways!
- Flora underexplored for drug discovery



**A reservoir of ethnobotanical knowledge informs resilient food security and health strategies in the Balkans**

Cassandra L. Quave<sup>1,2,\*</sup> and Andrea Pieroni<sup>3</sup>

**Economic Botany** Volume 70 Number 4  
April 2016  
Dedicated to Past, Present, and Future Uses of Plants by People



Published for The Society for Economic Botany  
by The New York Botanical Garden

NYBG



Springer

ISSN 1547-3351 (print)  
ISSN 1547-3369 (online)



**Forty-five years later: The shifting dynamic of traditional ecological knowledge on Pantelleria Island, Italy**

CASSANDRA L. QUAVE<sup>\*,1,2,3</sup> AND ALESSANDRO SAIITA<sup>4</sup>

## Journal of Ethnobiology and Ethnomedicine

Research

**Dermatological remedies in the traditional pharmacopoeia of Vulture-Alto Bradano, inland southern Italy**

Cassandra L. Quave<sup>\*1</sup>, Andrea Pieroni<sup>2</sup> and Bradley C. Bennett<sup>1</sup>

Open Access



ELSEVIER

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

SCIENCE @ DIRECT®

Journal of Ethnopharmacology 101 (2005) 258–270



Journal of  
ETHNO-  
PHARMACOLOGY

[www.elsevier.com/locate/jethpharm](http://www.elsevier.com/locate/jethpharm)

**Traditional pharmacopoeias and medicines among Albanians and Italians in southern Italy: A comparison**

Andrea Pieroni<sup>a,b,\*</sup>, Cassandra L. Quave<sup>c</sup>

# Albania, 2012





# Pantelleria, 2014



*Daphne gnidium* L., Thymelaceae



# Kosovo, 2015



# Aegadian Islands, 2017







# Interviews & Plant Collecting

- Prior informed consent
- Follow SEB/ISE Code of Ethics
- Access & Benefit Sharing



DNA barcoding




Herbarium Vouchers



# Access and Benefit Sharing


- Returning traditional knowledge to communities:
  - Book in local language
  - Community garden (ethnobotanical)
  - Community workshops
- Fostering training of local students and scientists
  - Research training workshops
  - University capacity building projects
  - Student exchange programs
- Collaboration agreements with local university partners and communities




# Plant Extraction




Dried 48-72 hrs



Vacuum-sealed with silica packets and shipped to lab



Pulverized with a grinder




1:10 extraction in 95% EtOH or MeOH for 2 x 72 hrs. or boiled in water for 30 minutes


# Plant Extraction




Plant materials separated from extract with vacuum filtration



Solvent removed under reduced pressure with a rotary evaporator



After freezing at  $-80^{\circ}\text{C}$ , extracts are lyophilized



Dried extracts scraped out and weighed


# Quave Natural Products Library (QNPL)

*Inspired by traditional medicine. Driven by bioactivity.*

- >1,400 botanical and fungal extracts
  - plus fractions from bioactive leads
- Library uniquely targets plants used in human medicine and food
- Existing extract library is:
  - Biodiverse:
    - 51 orders
    - >400 species
    - Linked to ethnobotanical use data



# Diversity of the Quave Natural Products Library (QNPL)





Total=418



- 5.50% Apiales
- 4.31% Asparagales
- 8.61% Asterales
- 2.63% Brassicales
- 4.78% Caryophyllales
- 2.39% Dipsacales
- 2.39% Ericales
- 6.94% Fabales
- 3.59% Fagales
- 1.67% Gentianales
- 12.44% Lamiales
- 2.15% Malpighiales
- 3.35% Malvales
- 20.57% Other (=4 per Order)
- 2.15% Pinales
- 3.59% Poales
- 3.11% Polyporales
- 2.15% Ranunculales
- 5.74% Rosales
- 1.91% Sapindales

	Species	Genera	Families	Orders
<b>Plants</b>	396	271	106	45
<b>Fungi</b>	22	22	11	6
<b>TOTAL</b>	<b>418</b>	<b>293</b>	<b>117</b>	<b>51</b>


# New solutions require innovative & timely screens



# New solutions require innovative & timely screens









- Opportunistic pathogen
- Leading cause of:
  - Bacteremia
  - Sepsis
  - Brain abscesses
  - Medical device infections
  - Skin and soft tissue infections (SSTI)
- Colonizes nasal passages of 30% healthy adults in US
- Commonly implicated in:
  - Bone and joint infections
  - Surgical site infections
  - Pneumonia
  - Endocarditis
- HA-MRSA vs. CA-MRSA

# Intrinsic Resistance: Biofilm

- Uni- or Poly-microbial
- Heightened gene exchange
- Slow growth/metabolism
- Matrix presents a physical barrier to host immune response and antibiotic therapy



# Elmleaf Blackberry


- Traditional uses in S. Italy:
  - Leaves: furuncles, abscesses, and other skin inflammations
  - Roots: hair loss
  - Fruits: eaten fresh and in marmalades
- One of 116 remedies related to SSTIs and other topical dermatological treatments identified
- 168 extracts screened
- Anti-biofilm activity first identified & published in 2008 and # 220 marked as possible lead




*Rubus ulmifolius* Schott. (Rosaceae): The source of the bioactive composition “220D-F2”.

Quave, C.L., A. Pieroni, and B.C. Bennett (2008) **Dermatological remedies in the traditional pharmacopoeia of Vulture-Alto Bradano, inland southern Italy.** *Journal of Ethnobiology and Ethnomedicine* 4:5.

Quave, C.L., L.R.W. Plano, \*T. Pantuso, and B.C. Bennett (2008). **Effects of extracts from Italian medicinal plants on planktonic growth, biofilm formation and adherence in MRSA.** *Journal of Ethnopharmacology* 118: 418-428



# Intrinsic Resistance: Biofilm







Ellagic acid glycosides from *Rubus ulmifolius* block biofilm formation and potentiate antibiotic clearance of biofilm on catheters.

Quave et al. (2012). Ellagic acid derivatives from *Rubus ulmifolius* inhibit *Staphylococcus aureus* biofilm formation and improve response to antibiotics. *PLoS ONE* 7(1): e28737.


Talekar et al. (2014). 220D-F2 from *Rubus ulmifolius* kills *Streptococcus pneumoniae* planktonic cells and pneumococcal biofilms. *PLoS ONE* 9(5): e97314.

220D-F2 improves response to functionally distinct classes of antibiotics, including daptomycin, clindamycin, vancomycin, and oxacillin.







# Synthetic library of glycosides (ellagic acid, catechol, phenol)



Synthesis of ellagic acid glycosides. a) TBSCl, Im, DMAP, CH<sub>2</sub>Cl<sub>2</sub>/DMF, 50°C, 36 h, 71%; b) TASF, CH<sub>2</sub>Cl<sub>2</sub>, room temperature, 1 min; then glycosyl donor, Bu<sub>4</sub>Ni (xyloside only), reflux, 48 h, 13-15%. c) 1) K<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O; 2) K<sub>2</sub>CO<sub>3</sub>, MeOH/H<sub>2</sub>O, 86-92%.




*The sugar is important!*




**Killing of planktonic pneumococci by 220D-F2.** *Streptococcus pneumoniae* strain D39 was inoculated in 24 well-plates containing THY and treated with DMSO or the indicated concentration of 220D-F2; treated cultures were incubated for 3 h at 37°C. Planktonic cells were removed (A) and then biofilms were washed and removed (B). Both populations were diluted and plated onto BAP to obtain CFU/ml. (C) Planktonic pneumococci treated for 3 h were also stained by the LIVE/DEAD assay and imaged using a fluorescent microscope. (Data: Vidal Lab)



**Killing of mature pneumococcal biofilms by 220D-F2.** *S. pneumoniae* D39 was inoculated and incubated for 8 h at 37°C after which mature biofilms were washed and added with fresh THY containing the indicated concentration of 220D-F2 or DMSO. Treated biofilms were incubated for (A) 3, (B) 6, or (C) 12 h at 37°C and then washed, diluted and plated onto BAP to obtain CFU/ml. (Data: Vidal Lab)



**Micrographs of 220D-F2 incubated with mature pneumococcal biofilms.** *S. pneumoniae* D39 was inoculated and incubated for 8 h at 37°C after which biofilms were washed and added with fresh THY containing the indicated concentration of 220D-F2 or DMSO. These treated mature biofilms were incubated for 3, 6 or 12 h and after washes, the biofilm structure was stained with DAPI (100 nM). Stained biofilms were imaged by fluorescence. (Data: Vidal Lab)






# CA-MRSA Epidemic

- Causes disease in otherwise healthy individuals
- Predominantly skin and soft tissue infections (~75%), but invasive disease is severe
- The most prevalent CA-MRSA isolates in the United States are USA400 (MW2) and USA300 (Los Angeles County clone, LAC)



# Prominent CA-MRSA are Highly Virulent\*



Voyich et al., *J Immunol*, 2005; *J Infect Dis*, 2006

\*First observed in humans

# *S. aureus* exotoxins cause serious disease



**Toxic Shock Syndrome Toxin (TSST-1)**  
Pyrogenic Toxin  
Superantigens




**Scalded Skin Syndrome**  
Exfoliative Toxins




**Abscesses, Necrosis, Sepsis**  
Hemolytic Toxins,  
Proteases, Lipases

# *S. aureus* immune evasion mechanisms




# Quorum Quenching Approach

- **Quorum quenching**
  - “Disarming” bacteria
  - Protect the host
  - Adjuvant to existing lines of antibiotics
- Accessory gene regulator (*agr*) system
  - controls virulence




# Quorum Quenching Approach

- **Quorum quenching**
  - “Disarming” bacteria
  - Protect the host
  - Adjuvant to existing lines of antibiotics
- Accessory gene regulator (*agr*) system
  - controls virulence





# Accessory Gene Regulator (*Agr*) System







# Chestnut

- Virulence Factors

- Attack host immune response
- Cause tissue damage
- Contribute to clinical failure in antibiotic therapy
- Controlled by cell-cell communication




Quave et al. (2015) *Castanea sativa* (European Chestnut) leaf extracts rich in ursene and oleanene derivatives block *Staphylococcus aureus* virulence and pathogenesis without detectable resistance. PLoS ONE 10(8): e0136486.






# Brazilian Peppertree



An exotic pest plant to some, a valued source of medicine to others. *Schinus terebinthifolia* Raddi is classified as a **Category I pest plant** by the Florida Exotic Pest Plant Council. Efforts to remove it from the United States have included the use of the herbicides triclopyr and glyphosate. On the other hand, its value as a medicinal plant has been broadly reported in South America

# Where to collect?






*Schinus molle* Radcl.  
Brazilian peppertree



General Information	
Symbol:	SCTE
Group:	Tree
Family:	Anacardiaceae
Duration:	Perennial
Growth Habit:	Shrub Tree
Native Status:	HI 1 LA 1 FL 1 MS 1 VA 1
Other Common Names:	Christmas berry whorls
Data Source and Documentation	





# Fractionation Scheme








*agr* P3-GFP reporters used to guide fractionation

# 430D-F5 inhibits *agr* in a non-biocide manner




# 430D-F5 mediates quorum quenching *in vivo* and attenuates MRSA-induced dermatopathology in a murine model of skin and soft tissue infection



## 430D-F5 impacts biofilm formation

# Characterization of 430D-F5 major constituents


(a) LC-FTMS ESI negative and positive base peak chromatograms for 430D-F5. (b) Putative structural matches are listed by peak number. Peak **2** was determined to be  $C_{30}H_{17}O_{10}$  and putative structural matches include: (**2a**) amentoflavone, (**2b**) agathisflavone, and (**2c**) robustaflavone. Peak **4** was determined to be  $C_{30}H_{21}O_{10}$  and putative structural matches include: (**4a**) chamaejasmin, (**4b**) tetrahydroamentoflavone, and (**4c**) tetrahydrorobustaflavone. Peak **14** was determined to be  $C_{30}H_{45}O_4$  and putative structural matches include: (**14a**) albsapogenin, (**14b**) (13 $\alpha$ ,14 $\beta$ ,17 $\alpha$ ,20R,24Z)-3 $\alpha$ -hydroxy-21-oxolanosta-8,24-dien-26-oic acid, (**14c**) (13 $\alpha$ ,14 $\beta$ ,17 $\alpha$ ,20S,24Z)-3 $\alpha$ -hydroxy-21-oxolanosta-8,24-dien-26-oic acid, (**14d**) (3 $\alpha$ ,13 $\alpha$ ,14 $\beta$ ,17 $\alpha$ ,24Z)-3-hydroxy-7-oxo-lanosta-8,24-dien-26-oic acid, and (**14e**) mollinoic acid. Peak **19** was determined to be  $C_{30}H_{45}O_4$  and putative structural matches include (**19**) isomasticadienonic acid.



# 430D-F5 has limited impact on growth of commensal skin microflora

Species	Strain	MIC	430D-F5	Antibiotic Controls*			
				Amp	Clin	Erm	Van
<i>Corynebacterium amycolatum</i>	SK46	MIC <sub>50</sub>	ND (512)	0.0625	-	0.00781	0.5
		MIC <sub>90</sub>	ND (512)	2	-	2	2
<i>Corynebacterium striatum</i>	FS-1	MIC <sub>50</sub>	ND (512)	ND (16)	-	1	0.5
		MIC <sub>90</sub>	ND (512)	ND (16)	-	2	0.5
<i>Micrococcus luteus</i>	SK58	MIC <sub>50</sub>	64	0.125	0.125	0.0625	0.25
		MIC <sub>90</sub>	128	0.125	0.5	0.0625	0.25
<i>Propionibacterium acnes</i>	HL005PA 2; HM-493	MIC <sub>50</sub>	16	-	0.125	0.125	-
		MIC <sub>90</sub>	256	-	0.125	0.5	-
<i>Staphylococcus epidermidis</i>	NIHLM00 1; HM896	MIC <sub>50</sub>	64	0.03125	-	-	1
		MIC <sub>90</sub>	ND (512)	0.0625	-	NT	1
<i>Staphylococcus haemolyticus</i>	NRS116	MIC <sub>50</sub>	64	ND (32)	-	ND (32)	1
		MIC <sub>90</sub>	ND (512)	ND (32)	-	ND (32)	2
<i>Staphylococcus warneri</i>	SK66	MIC <sub>50</sub>	64	0.0625	-	-	0.5
		MIC <sub>90</sub>	ND (512)	0.0625	-	-	1
<i>Streptococcus mitis</i>	F0392	MIC <sub>50</sub>	64	0.03125	-	0.00781	0.5
		MIC <sub>90</sub>	ND (512)	0.0625	-	0.03125	0.5
<i>Streptococcus pyogenes</i>	MGAS1525 2	MIC <sub>50</sub>	ND (512)	0.0156	0.125	0.0625	-
		MIC <sub>90</sub>	ND (512)	0.0313	0.125	0.0625	-



# Resistance Modification






# Beta-lactam antibiotics


- Class of broad-spectrum antibiotics, all which have a beta-lactam ring in their molecular structures
  - Penams (penicillin derivatives)
  - Cephems (cephalosporins)
  - Monobactams
  - Carbapenems
- Act by inhibiting synthesis of peptidoglycan layer of cell wall
  - Bactericidal
- Resistance occurs when enzymes breakdown the **beta-lactam ring**



# Screening Platform









# Fractional Inhibitory Concentration (FIC)



- $FIC = MIC \text{ drug [in presence of codrug]} / MIC \text{ drug alone}$
- $FIC \text{ Index} = \sum FIC_x + FIC_y$
- FICI
  - $< 0.5$  is synergistic
  - $0.5-4$  additive or no interaction
  - $> 4$  antagonistic

# Resistance Modifying Agents

- 25/900 extracts showed  $\beta$ -lactam sensitization (**3% hit rate from QNPL**)
- Extract 649 pursued due to high potency and lack of toxicity to human skin cells
  - History of use in Native American medicine as poultice for infected wounds and ulcers





# MIC Table

Ox breakpoint MIC = 2 µg/mL

Extract (µg/mL)	649		649B		649C		649D		649E	
	LAC	MW <sub>2</sub>	LAC	MW <sub>2</sub>	LAC	MW <sub>2</sub>	LAC	MW <sub>2</sub>	LAC	MW <sub>2</sub>
0	64	32	64	32	64	32	64	32	64	32
1	>8	>8	8	>8	8	>8	8	>8	>8	>8
2	>8	>8	8	>8	2	>8	>8	>8	>8	>8
4	1	>8	1	>8	1	>8	8	>8	8	>8
8	0.5	4	0.5	8	0.5	8	8	>8	>8	>8
16	0.25	2	0.5	2	0.25	2	>8	>8	8	>8
32	0.063	0.25	0.25	1	0.25	1	>8	>8	>8	>8

We achieved a **1,000-fold drop** in Oxacillin MIC (from 64 µg/mL to 0.063 µg/mL) with Extract 649

# Health in the balance



# Ethnobotany in the post-antibiotic era

- How can we use traditional knowledge of anti-infective remedies to innovate the next generation of therapeutics?
- Looking beyond 1940's paradigm of **kill, kill, kill....**
  - Anti-virulence
  - Evasion of pathogen defenses (e.g. biofilm)
  - Potentiation of existing therapeutics that have lost activity
  - Host-directed therapies
  - Achieving balance....
- Can we develop the right questions? ....only then can we find the right answers.

# Acknowledgements

## **Quave Lab & Herbarium (Emory)**

James T. Lyles, PhD  
Thara Samarakoon, PhD  
Angelle Bullard, PhD  
Amelia Muhs  
Akram Salam

Kate Nelson  
Joan Shang  
Matt Mendelsohn  
Micah Dettweiler

## **Weinert Lab (Emory)**

Alexander Horswill, PhD  
Jeff Kavanaugh, PhD  
Corey Parlet, PhD

Emily Weinert, PhD  
Ben Fontaine

## **Vidal Lab (Emory)**

Jorge Vidal, PhD  
Sharmila Talekar, PhD

Julia Kubanek, PhD  
Serge Lavoie, PhD

## **Kubanek Lab (Ga Tech):**

## **Melander Lab (NCSU)**

Christian Melander, PhD  
Roberta Melander, PhD

## **Fieldwork collaborators:**

Avni Hajdari, PhD (U. Prishtina, Kosovo)  
Alessandro Saitta, PhD (U. Palermo, Italy)  
Andrea Pieroni, PhD (U. Gastr. Sci., Italy)  
Alfonso La Rosa (Silene, Italy)



*Special thanks to all of the communities  
that have collaborated in our projects!*

Private Donors  
US Embassy in Kosovo  
Emory University

National Institutes of Health  
NIH/NCCIH R01 AT007052  
Georgia Research Alliance





# Questions?

